Ensuring Early Diagnosis and Targeting Treatment to Remission in Patients with Rheumatoid Arthritis: Recommendations for Primary Care Clinicians

Release date: June 21, 2019
Expiration date: June 21, 2020
Estimated time to complete activity: 0.75 hour(s)

 

FACULTY

Roy Fleischmann, MD
Clinical Professor of Medicine
Department of Medicine
University of Texas
Southwestern Medical Center
Dallas, Texas

PROGRAM OVERVIEW

Rheumatoid Arthritis (RA) imposes a significant healthcare burden in the US and many affected individuals continue to report poor quality of life despite ongoing treatment. Although numerous therapies are currently available, deficits in knowledge regarding their mechanisms of action and appropriate use, as well as inadequate compliance with published guidelines, remain persistent among clinicians. Additionally, many clinicians report a lack of awareness regarding the increase in risk for certain comorbidities and how to approach their management in patients with RA. Collectively, these observations indicate an important need for additional education regarding the early diagnosis of RA, the efficacy and safety of targeted therapies for treatment, and the implementation of a treat-to-target approach to disease management that takes into consideration the presence of comorbid conditions. With this in mind, this program has been developed to aid primary care clinicians, who are often at the frontline of care for individuals with RA, in acquiring the knowledge and skills required to improve the health outcomes of these patients.

TARGET AUDIENCE

This educational initiative has been designed for primary care physicians, physician assistants, and nurse practitioners involved in the management of patients with RA.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Implement routine screening to improve the early diagnosis of RA
  • Apply a treat-to-target approach that is consistent with current guideline recommendations for RA management
  • Describe the mechanisms of action of approved targeted therapies for the treatment of RA
  • Utilize strategies for early identification of important comorbidities and their management in patients with RA
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of June 21, 2019 through June 21, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Roy Fleischmann, MD
Advisory Boards: AbbVie, Eli Lilly & Company, Pfizer
Contracted Research: AbbVie, Eli Lilly & Company, Gilead, Pfizer

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Continue to Pretest